Introduction
Adeno-associated viruses (AAVs) are nonenveloped, nonpathogenic dependoviruses with a single-stranded genome approximately 4.7 kb in length of either positive or negative polarity. The replication of AAV necessitates a co-infection with helper virus such as adenovirus or herpes simplex virus. In the absence of helper virus, AAV integrates into the host chromosome to establish a latent infection. AAV has been isolated from many organisms including human, nonhuman primates, ovine, avian, snake, bovine, murine and caprine. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] It has been reported that various AAV serotypes have differing tropisms and can transduce specific organs more efficiently than others, such as the high transduction efficiency of AAV5 in airway epithelial, muscle and retina cells as compared to AAV2. 15, 16 Gene transfer vectors derived from AAV can deliver genes in a variety of tissues in vivo. Recent observations have also promoted the evaluation of AAV as potential genetic vaccine vectors due to their long-term expression profile that can stimulate robust antibody responses. 17, 18 Currently, clinical trials are taking place using AAV as a vector for the treatment of ailments such as Parkinson's disease, cystic fibrosis, Leber's congenital amaurosis, HIV infection and various other genetic disorders. [19] [20] [21] [22] These recombinant AAV (rAAV) vectors are based on the well-characterized human AAV serotype 2 which is seroprevalent in up to 80% of the human population with neutralizing antibodies found in 35% of them. 23 The AAV capsid proteins encoded by the cap gene were shown to be the main determinant for tissue tropism and constitute an important target for the immune response. The cap gene encodes three proteins expressed from two different alternatively spliced transcripts; VP1, VP2 and VP3. Some serotypes of AAV were found to be less immunogenic than others, which may translate into better gene transfer vehicle and less efficient vaccine vector or vice versa. 24, 25 In the past, AAV has conventionally been isolated from contaminated adenoviral stocks or young, sick animals or children. [1] [2] [3] [4] [5] [6] [7] 9, 12 Recently, isolation of new AAV isolates was extensively performed using PCR amplification of AAV sequences from genomic DNA of different animal species. 8, 10, 11, 13 In this study, novel porcine AAV sequences were identified by PCR using genome walking strategies. Although the isolation of parvoviruses from porcine tissues has been previously described, these viruses do not belong to the genus Dependovirus.
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We describe the isolation of a novel AAV2/po1 and the characterization of the serological profile and tissue tropism in vitro and in vivo. We hypothesize that AAVs of porcine origin will be highly compatible to human tissues. There have been documented examples demonstrating virus compatibility between human and porcine tissues including influenza and Nipah viruses. 29, 30 Reston Ebola virus may also provide another example of zoonotic transmission between pigs and humans (http://www.who.int/csr/don/2009_02_03/en/).
Results
Use of PCR to determine AAVpo1, -po2 and -po3 sequences from porcine tissues Because AAV has the ability to integrate its genome into the host chromosome during a latent infection, we utilized PCR techniques to isolate novel AAV sequences from genomic porcine DNA similarly to previous work reported by Gao et al. 8 and Mori et al. 11 Various pig tissues including heart, lung, spleen, liver and gut were harvested from rural private farms and industrial slaughterhouses, and DNA was isolated and screened for the presence of novel AAV sequences by PCR. The use of primers specific for conserved regions of the AAV genome generated at least three distinct AAV sequences from porcine tissues we called AAVpo1, AAVpo2 and AAVpo3 (GenBank accession numbers FJ688147, FJ688148 and FJ688146, respectively). A 258 bp sequence corresponding to the novel AAVpo1 was found in various organs from nine pigs obtained from three different locations. In contrast, the highly divergent 252 bp and 1.4 kb AAVpo3 sequence was only found in the intestine of one animal. Along with the unique porcine AAV sequences, other sequences highly similar (with 1-20 nucleotide changes throughout the cap gene) or identical to AAV2 cap were also isolated from approximately 12.5% of the porcine tissues screened. PCR amplification was also performed to isolate a 1.64 kb sequence that spans the rep and cap genes and a 1.4 kb sequence that overlaps with the 1.64 kb fragment and covers the 3 0 end of the cap gene. The entire cap gene of the AAVpo1 could be isolated from 63% of the tissues obtained from privately owned farmed pigs with the spleen having the highest success with 75% of AAV sequence recovery. Porcine lung, heart and liver were second for successful isolation of AAV sequences (data not shown). Only one farmed animal proved negative for AAV sequences, whereas tissue samples originating from the slaughterhouse showed only 4% of AAV sequence recovery from 51 samples. The fact that pigs obtained from privately owned farms tested positive for the presence of AAV more frequently than pigs from slaughterhouses could suggests that closer contacts of farmed pigs with humans could provide an environment for zoonotic transmission.
Alignment of the nucleotide sequence of AAVpo1, -po2 or -po3 with available AAV sequences revealed that AAVpo1 was more closely related to AAVgo.1, AAVpo2 to AAV2, and that AAVpo3 was uniquely divergent from the others (Figure 1 ). AAVpo1 cap showed 89.2% amino- Table 1 ). An alignment of the full or partial amino-acid sequences of cap for AAV5, -po1, -po2 or -po3 is also presented (Figure 2 ).
Production of AAV2/po1 hybrid vector
Several studies have demonstrated that AAV2 rep can trans-complement AAV cap gene resulting in successful production of functional AAV particles with the capsid protein of interest. Triple transfection of the transpackaging plasmid encoding for AAV2 rep and -po1 cap genes, a b-galactosidase (LacZ) expressing cis-plasmid and the helper plasmid containing the adenoviral genes necessary to drive production of AAV in human embryonic kidney 293T (HEK 239T) cells resulted in the successful generation of chimeric AAV2/po1 particles ( Figure 3 ). Purification of AAV2/po1 by cesium chloride gradient produced particles showing the distinct pattern of VP1, VP2 and VP3 on a denaturing acrylamide gel visualized by western blot using anti-VP1, -VP2 and -VP3 antibodies ( Figure 3a ). Protean software of DNASTAR Lasergene 7 predicted the VP1 protein of AAVpo1 to have 716 amino acids with a molecular weight of 80.18 kDa, and the VP1 protein of AAV5, used as a positive control, to contain 724 amino acids with a predicted molecular weight of 80.42 kDa. Electron microscopy revealed that AAVpo1 particles were comparable in shape and size to AAV2/5 with a diameter of 20-25 nm (Figure 3b ). Viral titers of 0.4 to 4 Â 10 13 genome copy (GC) per ml of AAV2/po1 per preparation of 3-4 ml could routinely be obtained as assessed by TaqMan PCR (see Materials and methods for details). Viral titers of 1.5 Â 10 13 GC per ml were obtained for AAV2/5 preparations (2.3 Â 10 5 GC per cell).
Transduction efficiency of AAV2/po1 in cultured cells
Transduction efficiency was evaluated for AAV2/po1 on different cell types in vitro. The closely related and highly characterized AAV2/5 vector was also evaluated in parallel and used as a benchmark. Subconfluent cell lines from different species including mouse fibroblasts (NIH 3T3), mouse macrophages (RAW 264.7), canine kidney cells (MDCK), fetal porcine retina cells (VR1BL E1), African green monkey kidney cells (VeroE6), human colorectal (CaCo), kidney (HEK 293T), liver (HepB2), lung (A549) and epithelial cells (HeLa) all were infected with 1 Â 10 9 GC of each AAV expressing LacZ and the number of positive blue cells was recorded after 48 h. Results, summarized in Table 1 , show that AAV2/po1 transduced all the cultured cell lines tested less efficiently than AAV2/5, with the exception of Vero E6 and VR1BL E1 cells. VR1BL E1 is a porcine retinal cell line that showed substantially higher susceptibility to AAV2/ po1 than AAV2/5. Residues that differ are displayed. Dashes indicate residues that are missing or have not been identified whereas dots indicate conserved amino acids. Alignments were performed using MegAlign from the DNASTAR Lasergene 7 software package.
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Tropism of AAV2/po1 in mice
The tropism and transduction efficiency of AAV2/po1 was studied in mice in parallel to AAV2/5 that was used as a control. A total of 1 Â 10 11 GC were administered per mouse in the muscle, liver or lung by intramuscular (i.m.), intravenous (i.v.) tail vein or intranasal injection and were harvested and analyzed 30 (liver and muscle) or 60 (lung) days after administration. LacZ-positive cells could not be detected in AAV2/po1-treated lungs and only rare scattered positive cells were observed in the liver (only anecdotal cells could be detected per 20 liver sections; data not shown). In contrast, high transduction efficiency was observed in the muscle following i.m. injection of AAV2/po1 that was comparable to that observed with AAV2/5 in the same conditions (Figure 4) . Similar b-gal activities were also recorded between AAV2/po1 and AAV2/5 at days 7 and 14 after transduction (Figure 4) . Expression of 0.415 ± 0.032 and 0.704±0.124 b-gal milliunits was obtained respectively at 7 and 14 days after administration of AAV2/po1-LacZ whereas AAV2/5-LacZ produced 0.425±0.011 and 0.815 ± 0.142 units of b-gal milliunits at days 7 and 14, respectively. Subretinal injections of AAV2/po1 also resulted in high transduction efficiency of the retinal pigment epithelium and photoreceptor layers again comparable to the efficiency recorded for AAV2/5 ( Figure 5 ). Cells in the inner nuclear layer and some cells morphologically similar to Muller cells were also transduced following AAV2/po1 administration. Interestingly, AAV2/po1 shows higher transduction efficiency in porcine retina cells when compared to AAV2/5, which may suggest species specificity. However, the efficient transduction of AAV2/po1 in the mouse retina is indicative of cell-type preference. One or both of these factors may explain the superior transduction of AAV2/po1 in VR1BL E1 porcine retinal cells.
Biodistribution of AAV2/po1 was also evaluated in mice from various organs 30 days after systemic administration by tail vein injection (Table 2) . Results showed that AAV GC numbers, established from the copy number of the lacZ gene per cell, were significantly lower for AAV2/po1 than for AAV2/5 in all organs studied with the exception of the muscle, although a high genome copy per cell was also detected in the spleen for AAV2/po1. Systemic administration of viral vectors including adenovirus or AAV results in strong targeting to the spleen that acts as a filter and traps incoming particles. This is a known fact to the field and constitutes mainly an undesirable event. We have focused on the muscle because it is an important tissue target with several gene therapy and/or vaccine applications.
Serological profile of AAV2/po1
Neutralization assays were performed with the antisera collected from AAV2/po1 and AAV2/5 intramuscularly injected mice to evaluate cross-neutralization between the two related isolates. Antiserum from AAV2/po1-or AAV2/5-treated mice had neutralizing antibody titer of 1:1280 or 1:5120 against themselves, respectively (Table 3 ). In contrast, AAV2/po1 antiserum had undetectable neutralizing antibody against AAV2/5 and vice versa. Overall, AAV2/po1 was not neutralized by sera collected from mice exposed to AAV2/2, -2/3, -2/4, -2/5, -2/6, -2/7 or -2/8 vector (data not shown). The AAV2/po1-and AAV2/5-expressing LacZ were also incubated with pooled Human Ig at various dilutions to address the serosusceptibility of the vectors to antibody found in humans. At least 50% of AAV2/5 particles were neutralized with 1.9 Â 10 À1 mg ml À1 of pooled human Ig whereas neutralization was not detected for AAV2/po1 with undiluted human Ig at 12 mg ml À1 (Table 3) . GC of vector. Cells were fixed and stained for b-galactosidase expression 48 h after being infected with AAV2/5-LacZ or AAV2/ po1-LacZ. Cells were infected at an MOI of 6 Â 10 2 GC per cell.
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Discussion
The present study reports the isolation of novel AAV sequences from porcine tissues and the generation of a new recombinant AAV2/po1 vector with unique properties. Human and porcine tissues are closely related and for this reason xenotransplantation of porcine tissue (for example, heart valves) is currently being performed with no evidence of toxic zoonotic transmission of infectious agents to human recipients despite their immunocompromised status. [31] [32] [33] We hypothesized that this high histocompatibility between porcine and human tissues would translate in porcine AAVs having good transduction efficiency and high safety profile for therapeutic applications in humans. An interesting observation is the isolation of AAV2 sequences identical or closely resem- The complete sequence of the cap gene of the isolate AAVpo1 was used to generate functional recombinant AAV2/po1 particles. The absence of cross-neutralization of AAV2/po1 with antiserum generated against all other serotypes evaluated and vice versa indicates that AAV2/ po1 is a distinct serotype and antigenically different from the other commonly used AAVs. The AAV2/po1 vector demonstrated strong tropism mainly for muscle fibers and the retinal pigment epithelium. Good transduction of muscle fibers combined with poor transduction of other tissues could make AAV2/po1 an attractive gene transfer vehicle for systemic delivery and potentially help the treatment of myopathies such as Duchenne muscular dystrophy. As per the methods described by Gonin et al., 34 injecting AAV2/po1 directly in the femoral artery and clamping of flow return and veins should result in increasing transduction of whole limb muscles while decreasing transduction of undesirable target organs. The absence of neutralizing antibody to AAV2/ po1 in pooled human sera constitutes an additional advantage for in vivo administration of the vector in humans. Finally, the generation of a novel AAV with a high tropism for the retina combined to a potentially low toxicity profile is likely to be of prime interest to the expanding scientific community focusing on ocular gene transfer.
Materials and methods
Isolation of genomic DNA from porcine tissues and amplification of AAV sequences
Various porcine tissues including the lung, heart, spleen, gut and liver were screened for the presence of AAV sequences. Porcine tissue samples were collected from various locations such as industrial slaughterhouses and private rural farms. Genomic DNA was isolated from approximately 25 mg of each tissue using QIAamp DNA Mini kit (Qiagen, Valencia, CA, USA). Primers SIG+ and SIGÀ (5 0 -GGTAATTCCTCGGGAAATTGGCATT-3 0 and 5 0 -GAATCCCCAGTTGTTGTTGATGAGTC-3 0 , respectively) were used to PCR-amplify short fragments referred as the 'signature region' as previously described by Gao et al. 8 These fragments of 252 and 258 bp corresponded to two novel AAV sequences from porcine tissues generating AAVpo1 and -po3 fragments. BLAST analysis showed that AAVpo1 and -po3 sequences were significantly different from previously described AAV sequences available on GenBank. The 5 0 sequence of cap was isolated with the primer RC+ described by Mori et al.
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; 5 0 -GGTGCGTAAACTGGACCAATGAGAAC-3 0 and the primer SIG-generating a 1.64 kb fragment encompassing the end of the rep gene and beginning of cap region. To isolate the 3 0 end of the cap gene, three successive primers were generated based on conserved regions of the AAV genome along with a reverse degenerate primer in a three-step nested thermal-asymmetric interlaced (TAIL) PCR. The three successive primers are PAAVSP1+ (5 0 -GGARATTGGCATTGCGATT CC-3 0 ), PAAVSP2+ (5 0 -GACTTCAACCGCTTCCACAGC CAC-3 0 ) and PAAVSP3+ (5 0 -GACTCATCAACAACCWA CTGGGG-3 0 ). The sequence of the degenerate primer CEDÀ is 5 0 -ACTGAMACGAAT(H/À)AMMCGGTTTAT TGA-3 0 . A 1.4 kb fragment that overlapped with the 1.64 kb 3 0 end sequence was isolated using these primers. Specific primers were also designed to isolate the fulllength cap gene from porcine tissues in one PCR with the following sequences: PO1CAPBEGIN+ (5 0 -ATGTAGTGG ATCTTGACGATG-3 0 ) and PO1CAPEND-(5 0 -CATGTGA CAGGATAGGGTTA-3 0 ). All PCR-amplified fragments were gel-purified using QIAguick Gel Extraction kit (Qiagen) and subsequently cloned into pCR2.1-TOPO Vector (Invitrogen, Carlsbad, CA, USA). DNA sequencing was performed by the DNA Core Facility at the National Microbiology Laboratory (NML). To rule out the possibility of AAV2 being a PCR artifact derived from plasmid DNA, all negative controls (consisting of water, buffer, dNTPs, primers and so on) that were negative at the time of isolation of AAV2 sequences were reanalyzed and remained negative. In addition, plasmid DNA containing AAV2 cap sequences were not present in the facility at the time of sequence isolation.
Production of hybrid AAV2/po1 particles
Chimeric AAV particles were produced with AAV2 rep and AAVpo1 cap expressing plasmids. AAVpo1 cap was cloned in place of the AAV cap gene in the packaging plasmid p600 trans using SwaI and NotI restriction sites, generating pACK 2/po1. The AAV2CMVLacZ or enhanced green fluorescent protein (EGFP) plasmids 35 expressing the lacZ or EGFP reporter genes from a cytomegalovirus (CMV) promoter and flanked by AAV2 inverted terminal repeats (ITRs) were used as the cis-plasmid containing the rAAV genome. Triple transfection of (HEK 293T) cells with AAV2CMVLacZ or EGFP, the packaging plasmids pACK2/po1 or pACK2/5 36 and the helper plasmid pAd.DELTA F6 containing adenoviral genes necessary to drive AAV replication (E2a, E4, VARNA) was performed with CaPO 4 as described previously. [37] [38] [39] HEK 293T cells were cultured using Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) and 1% penicillin/ streptomycin. Recombinant AAV vectors were all purified by CsCl 2 gradients as previously described. 38 Titers of AAV vector preparations were determined by TaqMan PCR for GC with primers LACZ+ (5 0 -TTAACCCGCCAT GCTACTTATCTA-3 0 ), LACZ-(5 0 -TGAACTAATGACCC CGTAATTGATT-3 0 ) and probe LACZP (5 0 -CTCTAGGAA GATCGGAATTCGCCCTTAAGCTAG-3 0 ) or with primers for the bGH polyA as previously described. 35 The number of transducing particles per GC was also determined for AAV2/po1 and AAV2/5 on HEK 293T cells (on average, for every 1 Â 10 9 GC, AAV2/po1 and AAV2/5 had 2 Â 10 5 and 4 Â 10 5 transducing units (TU) respectively). The AAV2/5-CMVEGFP and AAVpo1-CMVEGFP were produced by the Telethon Institute of Genetics and Medicine (TIGEM) AAV vector core. AAV specimens were prepared for electron microscopy by adsorption to glow discharged carbon coated formvar films on 400 mesh copper grids for one minute, and negatively contrasted with 2% methylamine tungstate (Nanoprobes, Yaphank, New York). 
Serology and neutralization assay
Recombinant AAV2/5 and AAV2/po1 vectors containing the lacZ transgene were injected intramuscularly into BALB/c mice (1 Â 10 11 GC per injection) in the left tibialis anterior. Serum samples were collected 28 days post infection for serology analysis. The sera were inactivated at 56 1C for 45 min. Serial dilutions of each sample (1:10, 1:20, 1:40, etc, in 50 ml of DMEM) was mixed with equal volume of the appropriate AAV encoding the lacZ reporter gene (80-100 TU per well) and incubated at 37 1C for 60 min. The mixture was then transferred onto subconfluent HEK 293T cells in 96-well flat-bottomed plates and incubated for 90 min at 37 1C in 5% CO 2 . Control wells were infected with equal amount of AAV vector without the addition of serum or with the addition of non-immune serum. DMEM (100 ml) supplemented with 20% FBS was then added to each well and the plates were incubated at 37 1C in 5% CO 2 for 48 h. Cells were subsequently stained with 5-bromo-4-chloro-3-indolyl b-D-galactoside (X-gal) and examined under a microscope. The same type of neutralization assay was also performed with Immune Globulin Intravenous Human Carimune NF (CSL Behring, King of Prussia, PA, USA) in place of the sera. Sample dilutions that showed 450% reduction in the number of LacZ-positive cells compared to controls scored positive for neutralizing antibody.
Histology and histochemical staining
For muscle gene delivery, the tibialis anterior was harvested 7, 14 or 30 days after i.m. injection of mice. The muscle was embedded in OCT medium and snapfrozen in liquid-nitrogen-cooled isopentane. For days 7 and 14 muscle samples, 10 sections cut at 40 mm were collected and b-gal activity was determined at an absorbance of 595 nm using Genlantis Enhanced BetaGal Assay kit (Genlantis, San Diego, CA, USA). For lung gene delivery, AAV2/5 or AAV2/po1 vector expressing LacZ was administered intranasally in BALB/C mice at 1 Â 10 11 GC per mouse in 50 ml. The lungs and trachea were harvested and inflated with a 1:1 solution of phosphate-buffered saline (PBS) and OCT medium 64 days after administration and embedded in OCT medium. For liver gene transfer, each mouse was injected in the tail vein with 1 Â 10 11 GC in 100 ml and the liver was harvested 30 days later and embedded in OCT medium. Lung, trachea and liver samples were frozen on ethanol-cooled dry ice. For all tissues, 10 mm thick sections were cut with a cryostat and fixed with 1.6% glutaraldehyde. The sections were then incubated overnight with X-gal at 37 1C, lightly stained with eosin and dehydrated in 70-100% ethanol solutions. Sections were analyzed on a light microscope.
Subretinal injections and retinal transduction assessment
All procedures on animals were performed in accordance with institutional guidelines of the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Four-week-old male C57BL/6 mice (Harlan, Milan, Italy) were used for injections of rAAV vector. Before vector administration, mice were anesthetized with an intraperitoneal injection of avertin (1.25% (wt/vol) 2,2,2-tribromoethanol and 2.5% (vol/vol) 2-methyl-2-butanol (Sigma-Aldrich, St Louis, MO, USA)) at 2 ml per 100 g of body weight. Subretinal vector administrations were performed as described previously using 1 ml of a vector solution containing 1 Â 10 12 GC per ml. A month after vector administration, mice were killed and their eyeballs were harvested and fixed overnight by immersion in 4% paraformaldehyde. The eyeballs were cut so that the lens and vitreous could be removed, leaving the eyecup. Mice eyecups were infiltrated with 30% sucrose for cryopreservation and were embedded in tissue-freezing medium (OCT matrix; Kaltek, Padova, Italy). For each eye, 150-200 serial sections (10 mm thick) were cut along the horizontal meridian, and the sections were progressively distributed on 10 slides so that each slide contained 15-20 sections representative of the whole eye at different levels. The sections were mounted with Vectashield (Vector Laboratories Inc., Peterborough, UK), and retinal histology images were obtained with an Axiocam (Carl Zeiss, Oberkochen, Germany) at Â 20 magnification.
Biodistribution in mice
AAV2/5 or AAV2/po1 expressing LacZ was administered at 1 Â 10 11 GC in 100 ml PBS per C57BL/6 or BALB/c mouse by i.v. tail vein injection. Various organs including the heart, liver, spleen, kidney, lungs, small intestine, large intestine, muscle and pancreas were collected 28 days after injection and analyzed by TaqMan analysis for the amount of rAAV GC per cell. Briefly, DNA was extracted from approximately 25 mg of each tissue sample with QIAamp DNA Mini kit and TaqMan amplification was performed as described previously 40 with the primers LACZ+, LACZÀ and probe LACZP described above. The signal was considered positive when the number of GC was superior to three times of the number obtained from PBS-injected control tissues. The number of transduced rAAV genomes in each organ is reported as number of GC per cell (500 ng DNA contained within 1.5 Â 10 4 cells). All animal studies were approved by the Canadian Council on Animal Care at the NML of the Public Health Agency of Canada.
Statistical analysis
Data were analyzed for statistical difference by performing unpaired t-test or one-way analysis of variance when appropriate. The differences in the mean or raw values among treatment groups were considered significant when Po0.05.
